Acadia Pharmaceuticals
Open
$21.15
Prev. Close
$21.17
High
$21.17
Low
$21.05
Market Snapshot
$3.6B
9.6
1.37
$957.8M
796
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The firm is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. The company is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The firm is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. The company is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Recently from Cashu
Acadia Pharmaceuticals Announces Dr. Elizabeth H.Z. Thompson's Retirement and Continued Consulting Role
Acadia Pharmaceuticals announces the upcoming retirement of Dr. Elizabeth H.Z. Thompson, the current Head of Research and Development. Dr. Thompson will transition out of her role while continuing her…
Acadia Pharmaceuticals Launches DAYBUE STIX for Effective Rett Syndrome Treatment
Acadia Pharmaceuticals announces the rollout of DAYBUE STIX, a cutting-edge powder formulation of trofinetide for patients with Rett syndrome. This launch follows FDA approval granted in December 2025…
Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome After FDA Approval
Acadia Pharmaceuticals announces the launch of DAYBUE STIX, a new powder formulation of trofinetide, tailored for patients aged two and older with Rett syndrome. This announcement comes on the heels o…
Please provide the article content that you want summarized, and I will assist you!
I'm sorry, but I need the specific text or article content in order to create a summary. Please provide the text you want summarized, and I will be happy to help!